Japan makes a bold move to administer remdesivir for COVID-19 patients.

With the increasing number of cases in Japan, healthcare officials have taken a bold move to administer the experimental drug remdesivir for severely affected COVID-19 patients.

In a recent article, Japan’s health minister said healthcare officials are administering severely affected COVID-19 patients with Gilead Sciences drug remdesivir, days after an emergency approval was given after the drug showing positive effects on affected.

In an Email, Japan’s Ministry official Yasuyuki Sahara stated that the US based company drug has been distributed to hospitals all over Japan, and is being administered to patients severely affected or in ventilators. It was also mentioned that the drug supply is quite limited.

With almost 16,000 infections and 687 deaths from the coronavirus outbreak, Japan has way fewer cases compared to other industrialized nations. In a specific ventilator, cases are about 259 and on May 1st, Japan made Remedisivr to be the first approved drug in the country to treat the virus. Currently, the US-based company Gilead has pledged around 1.5 million doses of remdesivir to Japan.

With no confirmed approved treatments for COVID-19, remdesivir is increasing in popularity all over the world.  Administered intravenously, it was granted the authorisation by the U.S. Food and Drug Administration for emergency use. Gilead’s released studies showing that the drug shows good improvement in the affected when given at the early stages of the infection.

To know more about origin, virology of COVID-19, Click here

To know more about emerging themes in COVID-19, Click here

To know more about how WhiteCoats can help you in your professional advancement, visit www.whitecoats.com

Want to set up an online consultation for your practice, Click here